Lurbinectedin for cancers with specific EWS-related gene fusions
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests lurbinectedin, a chemotherapy medicine, in children and young adults whose solid tumors have a specific “FET fusion” gene change. It may help shrink tumors that have come back or did not respond to prior treatment, depending on the exact fusion type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 10 years old.
- Your tumor must have a confirmed FET gene fusion (involving EWSR1, FUS, or TAF15) using lab tests like sequencing, PCR, or FISH.
- Your cancer must be recurrent or relapsed and have failed prior treatment (for Phase 2, it’s Ewing sarcoma with the EWS-FLI1 fusion).
- Your performance status must be good enough for study treatment (ECOG 0–1 if over 16, or Lansky 70+ if under 16).
- Your most recent scans must show measurable disease within 28 days of starting treatment, and you must meet blood, liver, kidney, and heart requirements.
- You cannot have had lurbinectedin or trabectedin before, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
This study is testing new drugs for young people (ages 10 and up) with Ewing sarcoma or related tumors that have come back or stopped responding to treatment. The goal is to find promising drugs that may help shrink tumors or slow their growth.
This trial tests a new type of immunotherapy that targets a specific genetic change in Ewing sarcoma and a related rare tumor called DSRCT. It may be an option for patients whose cancer has come back, spread, or is very high-risk after standard chemotherapy.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.